Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,979

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

The Future of Peptide‐based Drugs

Craik, David J., Fairlie, David P., Liras, Spiros, Price, David·2013·Chemical Biology & Drug Design
DOI 10.1111/cbdd.12055
Open this paper in CoChat — free account

Abstract

The suite of currently used drugs can be divided into two categories – traditional ‘small molecule’ drugs with typical molecular weights of <500 Da but with oral bioavailability, and much larger ‘biologics’ typically >5000 Da that are not orally bioavailable and need to be delivered via injection. Due to their small size, conventional small molecule drugs may suffer from reduced target selectivity that often ultimately manifests in human side‐effects, whereas protein therapeutics tend to be exquisitely specific for their targets due to many more interactions with them, but this comes at a cost of low bioavailability, poor membrane permeability, and metabolic instability. The time has now come to reinvestigate new drug leads that fit between these two molecular weight extremes, with the goal of combining advantages of small molecules (cost, conformational restriction, membrane permeability, metabolic stability, oral bioavailability) with those of proteins (natural components, target specificity, high potency). This article uses selected examples of peptides to highlight the importance of peptide drugs, some potential new opportunities for their exploitation, and some difficult challenges ahead in this field.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cbdd.12055

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 73

  1. 10.1016/S1056-8719(00)00107-6 · DOI · Paper page
  2. 10.1039/c0cs00029a · DOI · Paper page
  3. 10.1136/bmj.39024.487720.68 · DOI · Paper page
  4. 10.1007/978-0-387-73657-0_201 · doi:10.1007/978-0-387-73657-0_201
  5. 10.1016/j.drudis.2009.10.009 · DOI · Paper page
  6. 10.1517/17460441.2012.661554 · DOI
  7. 10.1021/cr900368a · DOI · Paper page
  8. 10.1021/cr900395y · DOI
  9. 10.1016/B978-0-12-396962-0.00001-X · DOI · Paper page
  10. 10.1016/B978-0-12-396962-0.00013-6 · doi:10.1016/b978-0-12-396962-0.00013-6
  11. 10.1016/j.cbpa.2011.02.015 · DOI
  12. 10.1016/j.tips.2010.06.003 · DOI
  13. 10.2174/092986712799945003 · DOI · Paper page
  14. 10.1517/17460441.2011.632002 · DOI
  15. 10.1517/14656566.2012.692777 · DOI
  16. 10.1021/bc700292v · DOI
  17. 10.1016/j.jconrel.2008.09.091 · doi:10.1016/j.jconrel.2008.09.091
  18. 10.1039/b819311h · DOI
  19. Borel J.F., 2002, History of the discovery of cyclosporin and of its early pharmacological development, Wien Klin Wochenschr, 114, 433
  20. 10.1126/science.1125248 · DOI · Paper page
  21. 10.1039/c0ob00139b · DOI
  22. 10.1111/j.1365-313X.2011.04626.x · DOI
  23. 10.1038/nchembio.664 · DOI · Paper page
  24. 10.1021/ja303200d · DOI · Paper page
  25. Fairlie D.P., 1995, Macrocyclic peptidomimetics: forcing peptides into bioactive conformations, Curr Med Chem, 2, 672, 10.2174/0929867302666220218001506 · doi:10.2174/0929867302666220218001506
  26. 10.1021/ja063076p · DOI · Paper page
  27. 10.1021/ar8000603 · DOI · Paper page
  28. 10.1021/ar800064f · DOI · Paper page
  29. 10.1021/cr040648k · DOI · Paper page
  30. Fairlie D.P., 1998, Towards protein surface mimetics, Curr Med Chem, 5, 29, 10.2174/0929867305666220314194822 · doi:10.2174/0929867305666220314194822
  31. 10.1021/ja0456003 · DOI · Paper page
  32. 10.1186/1472-6807-8-54 · DOI
  33. 10.1093/nar/gkm939 · DOI
  34. 10.2174/138161211798999438 · DOI
  35. 10.1002/anie.201102190 · DOI
  36. 10.1152/physrev.00020.2003 · DOI · Paper page
  37. 10.1002/(SICI)1098-2299(199903/04)46:3/4<219::AID-DDR7>3.0.CO;2-S · doi:10.1002/(sici)1098-2299(199903/04)46:3/4<219::aid-ddr7>3.0.co;2-s
  38. 10.1039/b307632f · doi:10.1039/b307632f
  39. 10.1021/cr040669e · DOI · Paper page
  40. 10.1016/j.cbpa.2008.08.019 · DOI · Paper page
  41. 10.1073/pnas.1002498107 · DOI · Paper page
  42. 10.1002/bip.10203 · DOI · Paper page
  43. 10.1016/j.bmcl.2011.01.004 · DOI
  44. 10.1038/nprot.2011.324 · DOI · Paper page
  45. 10.1021/ja206074j · DOI · Paper page
  46. 10.1021/jm030210x · doi:10.1021/jm030210x
  47. 10.1021/ja002416i · doi:10.1021/ja002416i
  48. 10.1021/ja900047w · DOI
  49. 10.1016/0014-5793(90)81040-U · doi:10.1016/0014-5793(90)81040-u
  50. 10.1002/pro.5560031206 · DOI · Paper page
  51. 10.2174/187152109789760216 · DOI
  52. 10.1016/S0040-4020(01)90214-5 · DOI
  53. 10.1016/j.coph.2003.06.003 · DOI
  54. 10.2174/1381612033454900 · doi:10.2174/1381612033454900
  55. 10.1021/cr040689g · DOI · Paper page
  56. 10.1016/j.drudis.2009.10.007 · DOI
  57. 10.1021/jm101018r · DOI
  58. 10.1021/bc9003102 · doi:10.1021/bc9003102
  59. 10.1021/bc900361g · doi:10.1021/bc900361g
  60. 10.1158/0008-5472.CAN-08-2495 · DOI
  61. 10.1073/pnas.96.23.13091 · DOI
  62. 10.1182/blood-2011-06-359141 · DOI · Paper page
  63. 10.1021/jm800704e · DOI · Paper page
  64. 10.1021/jm901233u · DOI
  65. 10.1002/anie.201200984 · DOI · Paper page
  66. 10.1016/j.jconrel.2011.08.030 · DOI
  67. 10.1074/jbc.M111.264424 · DOI · Paper page
  68. Bowersox S., 1997, Pharmacokinetics of SNX‐111, a selective N‐type calcium channel blocker, in rats and cynomolgus monkeys, Drug Metab Dispos, 25, 379
  69. 10.2174/0929867043363884 · DOI · Paper page
  70. 10.1002/anie.201000620 · DOI · Paper page
  71. 10.2174/138161211798999401 · doi:10.2174/138161211798999401
  72. 10.1007/s00018-009-0159-3 · doi:10.1007/s00018-009-0159-3
  73. 10.1039/c1cc12647d · DOI

Cited by

See all 1,979

Metadata

Authors
Craik, D. J., Fairlie, D. P., Liras, S., & Price, D.
Venue
Chemical Biology & Drug Design
Publisher
Wiley
Published
2012-12-17
Volume
81
Issue
1
Pages
136-147
ISSN
  • 1747-0277 (ISSN-L)
  • 1747-0285
DOI
10.1111/cbdd.12055
OpenAlex
W1860382351
Cited by
1,979
References
7
FWCI
32.30
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.